Novo Nordisk Sees Obesity Drug Fueling Record Profit

The transcript discusses the market demand and launch plans for a new obesity drug, highlighting the significant opportunity in the US and European markets. It covers the challenges of supply chain management, differences in market dynamics between the US and Europe, and the importance of insurance coverage. The discussion also touches on the health implications of obesity and the potential for government reimbursement in Europe.

What is the addressable market for obesity drugs in the US?

What progress has been made regarding government reimbursement for obesity drugs in Europe?